Which manufacturer is Selumetinib from?

Selumetinib was developed and produced by AstraZeneca in the UK. Selumetinib(Selumetinib) was released in20204Menstruation AmericaFDA was approved for marketing and will be launched in China on 20234month28. Selumetinib belongs to the kinase inhibitor class of drugs. Selumetinib is used to treat 1 type Neurofibromatosis(NF1).

Selumetinib is a non-ATP competitive inhibitor of mitogen-activated protein kinase kinase kinases 1 and 2 (MEK1 and MEK2). By selectively targeting MEK1 and MEK2, selumetinib inhibits the oncogenic downstream effects of the Raf-MEK-ERK signaling pathway, which are often overactive in certain types of cancer. In fact, one study examining the effects of selumetinib in children with NF-1 found that treatment with the anti-tumor drug reduced tumor size. Reductions in tumor-related pain and improvements in overall function were also subjectively reported. Selumetinib has minimal off-target activity, which contributes to its impressive safety profile. Selumetinib is characterized by a short half-life, the elimination half-life in pediatric patients is 6.2 hours when the dose is 25mg/cubic meter. In a study looking at the pharmacokinetic effects of different selumetinib regimens in selected Japanese patients, the half-life was 9.2- 10.6 hours. In other studies with 75 mg of selumetinib administered twice daily, the half-life was reported to be approximately 13 hours. Original version of selumetinib is available overseas, retail price10mg60tablets50000About. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.